Up 6%, guess which ASX 200 stock is the best performing so far today

ASX 200 healthcare share Imugene is leading the market today.

| More on:
Group of Imugene scientists cheering in the lab after the company received another patent for HER-Vaxx

Image source: Getty Images

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Key points

  • ASX 200 healthcare stock Imugene is leading the market today, up 6% at lunchtime 
  • The company hasn't released any news today but made a price-sensitive announcement last week 
  • Imugene announced its treatment for liver cancer had been featured in a pre-conference presentation ahead of the American Society of Gene and Cell Therapy’s Annual Meeting (ASGCT) later this month

S&P/ASX 200 (ASX: XJO) stocks are down 0.3% at lunchtime on Tuesday, but as always, there are outliers.

Today, ASX healthcare stock Imugene Limited (ASX: IMU) is leading the ASX 200 with its share price up 6% to 12 cents.

The immuno‐oncology biotech hasn't released any announcements to the market today.

However, Imugene released some price-sensitive news last week, so let's look at that.

What's pushing this ASX 200 stock higher?

Imugene is a biotech ASX 200 stock. The company is developing immunotherapies to treat and kill cancerous tumours and is currently conducting several clinical trials.

Last week Imugene announced that its onCARlytics technology was featured in an abstract ahead of the American Society of Gene and Cell Therapy's Annual Meeting (ASGCT) on 16 May to 20 May.

An abstract is essentially a pitch to conference organisers in the hope of a formal invitation to present at the conference itself.

Opportunities to present at medical conferences are important for rising biotechs like Imugene.

These events can garner interest from new investors and potential future customers (i.e., the attending medical practitioners.)

The abstract outlined the effectiveness of combination immunotherapy using Imugene's onCARlytics technology together with Eureka Therapeutics' Artemis T cell platform to treat hepatocellular carcinoma (HCC).

HCC is the most primary type of liver cancer and the sixth most common cancer in the world.

In a statement, Imugene said:

While hepatocellular carcinoma (HCC) has systemic therapies and curative treatment options, CD19 targeting CAR T cell therapy has shown positive clinical outcomes, despite some ongoing challenges in bringing effective results into solid cancers.

… the combination strategy can be applied to otherwise target-less tumours such as HCC, and this shows the potential this could be applicable to a wide array of solid cancers as an effective immunotherapy approach.

Imugene has presented at several conferences already in 2023.

They include the prestigious J.P. Morgan Healthcare Conference, which attracts thousands of global investors every year.

Imugene has also presented at the ASCO Gastrointestinal Cancers Symposium and the NWR Healthcare Conference.

Imugene share price snapshot

This ASX 200 stock is down 13% in 2023 while the S&P/ASX 200 Health Care Index (ASX: XHJ) is up 8%.

Created with Highcharts 11.4.3Imugene PriceZoom1M3M6MYTD1Y5Y10YALLwww.fool.com.au

Motley Fool contributor Bronwyn Allen has no position in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

More on Healthcare Shares

Overjoyed man celebrating success with yes gesture after getting some good news on mobile.
Healthcare Shares

Which small cap ASX share is jumping 10% on strong results

Investors have been bidding this stock higher today. But why?

Read more »

Cropped shot of an attractive young female scientist working on her computer in the laboratory.
Healthcare Shares

Why Macquarie forecasts 30-50% upside for these ASX All Ords healthcare stocks

Macquarie updated its target price on these three ASX All Ords healthcare stocks.

Read more »

A woman jumps for joy with a rocket drawn on the wall behind her.
Healthcare Shares

Guess which ASX 200 stock is jumping 10% on big news

This stock is catching the eye with a strong gain on Thursday. But why?

Read more »

a young woman holds her hand to her ear and leans sideways as if to listen to something that's surprising her as her eyes and her mouth are wide open.
Healthcare Shares

Down 15% since January, are Cochlear shares now a buy?

Let's see what analysts are saying about this blue chip.

Read more »

Green arrow with green stock prices symbolising a rising share price.
Healthcare Shares

Guess which popular ASX 200 stock is up nearly 60% in less than 2 months?

Investors who bought this ASX 200 stock in the recent dip have been strongly rewarded.

Read more »

A senior pharmacist talks to a customer at the counter in a shop.
Healthcare Shares

Are Sigma Healthcare shares a good buy now after the merger with Chemist Warehouse?

Sigma Healthcare shares have soared 154% in 12 months. Can this stellar run continue?

Read more »

Doctor doing a telemedicine using laptop at a medical clinic
Healthcare Shares

Up 34% since April, ASX 300 healthcare stock lifts off again today on new milestone

The ASX 300 healthcare stock has been on a tear since hitting one-year lows in April.

Read more »

Shot of a scientist using a computer while conducting research in a laboratory.
Healthcare Shares

Should I buy the dip on CSL shares?

A leading fund manager gives his verdict on the growth prospects for CSL shares.

Read more »